Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RAPP
stocks logo

RAPP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 53.00 USD with a low forecast of 34.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 53.00 USD with a low forecast of 34.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 28.700
sliders
Low
34.00
Averages
53.00
High
80.00
Current: 28.700
sliders
Low
34.00
Averages
53.00
High
80.00
BTIG
NULL -> Buy
initiated
$47
2025-11-18
Reason
BTIG
Price Target
$47
2025-11-18
initiated
NULL -> Buy
Reason
BTIG initiated coverage of Rapport Therapeutics with a Buy rating and $47 price target. Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions, the analyst tells investors in a research note. BTIG has a high degree of confidence that the Phase 3 registrational focal epilepsy trials for RAP-219 will be successful and that the drug will receive approval.
Citizens JMP
Outperform
maintain
$77 -> $80
2025-11-07
Reason
Citizens JMP
Price Target
$77 -> $80
2025-11-07
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Rapport Therapeutics to $80 from $77 and keeps an Outperform rating on the shares. Rapport reported Q3 results and said it continues to advance RAP-219 development, the analyst tells investors in a research note. The firm continues to believe that the results from the Phase 2a proof-of-concept study evaluating RAP-219 in focal epilepsy can be rapidly and broadly adopted in clinical practice.
Truist
Joon Lee
Buy
initiated
$44
2025-09-16
Reason
Truist
Joon Lee
Price Target
$44
2025-09-16
initiated
Buy
Reason
Truist analyst Joon Lee initiated coverage of Rapport Therapeutics with a Buy rating and $44 price target. Rapport is focused on the central nervous system with a lead program in focal onset epilepsy, a therapeutic area worth $10B annually and growing, the analyst tells investors in a research note. The firm believes RAP-219's magnitude and speed of seizure reduction is "impressive" and models over$1B in peak sales in 2038 for focal onset epilepsy alone.
Goldman Sachs
Salveen Richter
maintain
$51
2025-09-12
Reason
Goldman Sachs
Salveen Richter
Price Target
$51
2025-09-12
maintain
Reason
Goldman Sachs analyst Salveen Richter assigned Rapport Therapeutics with a Buy rating and $51 price target from its Early-Stage Biotech designation. RAP-219's Phase 2 epilepsy data showed a 71% reduction in long episodes, the primary endpoint, with 24% achieving seizure freedom for the eight-week treatment period, the analyst tells investors in a research note. Goldman now views RAP-219 as well-positioned into the Phase 3 study given the Phase 2 "de-risking."
H.C. Wainwright
Buy
upgrade
$31 -> $34
2025-09-08
Reason
H.C. Wainwright
Price Target
$31 -> $34
2025-09-08
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Rapport Therapeutics to $34 from $31 and keeps a Buy rating on the shares. The firm says RAP-219 surpassed its "most bullish expectations" with 71% reduction in long episodes and 78% reduction in clinical seizures. The data show "unimpeachable evidence" of the drug's effect and provide "strong evidence that it has the potential to become a mainstay" in the treatment of focal onset seizures, the analyst tells investors in a research note. H.C. Wainwright increased its probability of sucess for oral RAP-219 to 66% and peak revenue estimate to $766M from $613M.
Stifel
Buy
maintain
$35 -> $56
2025-09-08
Reason
Stifel
Price Target
$35 -> $56
2025-09-08
maintain
Buy
Reason
Stifel raised the firm's price target on Rapport Therapeutics to $56 from $35 and keeps a Buy rating on the shares after the company reported topline RAP-219 Phase 2a data in focal onset seizures that the firm says "clearly exceeded expectations." The effect-size is "so large that we are increasingly confident" in the probability-of-success for the Phase 3 trial, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rapport Therapeutics Inc (RAPP.O) is -8.88, compared to its 5-year average forward P/E of -6.10. For a more detailed relative valuation and DCF analysis to assess Rapport Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.10
Current PE
-8.88
Overvalued PE
-3.79
Undervalued PE
-8.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.51
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.95
Undervalued EV/EBITDA
-6.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RAPP News & Events

Events Timeline

(ET)
2025-11-06
07:05:41
Rapport Therapeutics announces Q3 earnings per share of 71 cents, below consensus estimate of 73 cents.
select
2025-09-09 (ET)
2025-09-09
22:02:04
Rapport Therapeutics Prices 9.62M Share Secondary Offering at $26.00
select
2025-09-08 (ET)
2025-09-08
16:06:29
Rapport Therapeutics reveals $250 million common stock sale
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-20Benzinga
Extreme Networks Analyst Starts Coverage with Optimism; Check Out the Top 5 Initiations for Wednesday

  • Analyst Ratings Overview: Top Wall Street analysts have recently changed their outlook on several companies, providing new ratings and price targets.

  • Rapport Therapeutics Inc: BTIG analyst Kambiz Yazdi initiated coverage with a Buy rating and a price target of $47, while shares closed at $27.01.

  • Riot Platforms Inc: Citizens analyst Greg Miller initiated coverage with a Market Outperform rating and a price target of $25, with shares closing at $13.42.

  • Extreme Networks Inc and Others: B of A Securities and Canaccord Genuity also initiated coverage on Extreme Networks and Insight Enterprises, respectively, with price targets of $24 and $100, while UBS rated Parsons Corp with a Buy and a target of $107.

[object Object]
Preview
6.5
11-03MarketWatch
Biotech Makes a Comeback: Reasons to Add These Rising Stocks to Your Portfolio Today.

  • Biotech Sector Recovery: Biotech stocks are rebounding after a four-year downturn, with the SPDR S&P Biotech ETF (XBI) rising 25% year-to-date as of October 31.

  • Performance Comparison: The biotech sector's performance has outpaced the S&P 500 by 9 percentage points during the same period.

  • Future Outlook: Analysts believe that the strength of the biotech sector is likely to persist, indicating potential opportunities for investors.

  • Investment Timing: Experts suggest that it is not too late for investors to enter the biotech market.

[object Object]
Preview
9.0
09-22NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading on Friday in Anticipation of Important Clinical Trial Announcements

  • MBX Biosciences Surge: MBX Biosciences Inc. saw a 33% increase in after-hours trading, driven by anticipation of topline results from its Phase 2 trial of Canvuparatide for chronic hypoparathyroidism, scheduled for release on September 22.

  • Structure Therapeutics Growth: Structure Therapeutics Inc. experienced an 11.37% rise in after-hours trading, fueled by interest in its lead candidate aleniglipron, currently in Phase 2b trials for obesity, with topline results expected by the end of 2025.

  • Cartesian Therapeutics Update: Cartesian Therapeutics Inc. gained 5.51% in after-hours trading, with preliminary data from its Phase 2 trial of Descartes-08 for systemic lupus erythematosus expected in late 2025, while maintaining sufficient cash reserves to support operations through mid-2027.

  • Rapport and Rezolute Movements: Rapport Therapeutics Inc. rose 3.60% following positive Phase 2a trial results for RAP-219, while Rezolute Inc. increased 3.77% after reporting fiscal results and confirming upcoming topline data from its Phase 3 trial for congenital hyperinsulinism expected in December 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rapport Therapeutics Inc (RAPP) stock price today?

The current price of RAPP is 28.7 USD — it has increased 3.39 % in the last trading day.

arrow icon

What is Rapport Therapeutics Inc (RAPP)'s business?

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

arrow icon

What is the price predicton of RAPP Stock?

Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 53.00 USD with a low forecast of 34.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rapport Therapeutics Inc (RAPP)'s revenue for the last quarter?

Rapport Therapeutics Inc revenue for the last quarter amounts to -29.99M USD, increased 38.57 % YoY.

arrow icon

What is Rapport Therapeutics Inc (RAPP)'s earnings per share (EPS) for the last quarter?

Rapport Therapeutics Inc. EPS for the last quarter amounts to -17599000.00 USD, increased 6.31 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rapport Therapeutics Inc (RAPP)'s fundamentals?

The market is revising No Change the revenue expectations for Rapport Therapeutics, Inc. (RAPP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 99.86%.
arrow icon

How many employees does Rapport Therapeutics Inc (RAPP). have?

Rapport Therapeutics Inc (RAPP) has 69 emplpoyees as of December 05 2025.

arrow icon

What is Rapport Therapeutics Inc (RAPP) market cap?

Today RAPP has the market capitalization of 1.37B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free